In addition, direct oral supplementation of butyrate remarkably alleviates the liver fibrosis stage by decreasing the expression of inflammatory maker protein (MyD88) and alleviating liver steatosis and lipid degeneration of NASH mice, interestingly, the inhibition of iNOS may be involved in the potential mechanism for butyrate alleviating NASH (21). The gene discussed is MYD88; the disease is metabolic dysfunction-associated steatohepatitis.